FALLYPRIDE
Lymphoid Malignancies
National Cancer Institute (NCI)Small moleculePhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Lymphoid Malignancies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Case Comprehensive Cancer Center | Phase 2 | BB |
Abt-263 AbbVie | Phase 1/2 | B |
Pralatrexate Jennifer Amengual | Phase 1/2 | CCC |
Venetoclax National Cancer Institute (NCI) | Phase 1/2 | CCC |
Romidepsin Columbia University | Phase 1/2 | CCC |
View all 21 →
Same molecule, other indications
FALLYPRIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →